Eli Lilly and Company's Q4 and ... pipeline and strong financial performance, Lilly is poised to potentially become the first trillion-dollar market cap pharma company by 2025.

Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The out-of-pocket cost cap of $£35 at participating ... and less than $8 in the UK. Eli Lilly together with Sanofi and Novo Nordisk make up 90% of the US market for insulin.

Ben Hargreaves explains how Eli Lilly decided to cap its insulin price ... guarantee to Medicare beneficiaries that insulin costs would be capped at $35. In California, the state had used $ ...

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...